Background: Sepsis is characterized as an infection that causes potentially fatal organ malfunction as a result of a dysregulated patient response to the infection (SSC), with septic shock being a subgroup of sepsis linked with greater fatality rates due to significant underlying metabolic, cellular, and circulatory abnormalities. This study aimed to evaluate the effects of midodrine on the weaning process off IV vasopressors as well as the drug's economic value.  Methods: This prospective controlled trial was executed on One hundred patients with septic shock. Patients were split into two equal groups: the norepinephrine group (IV norepinephrine only): patients were given intravenous vasopressor infusion and Midodrine group: given oral midodrine 10 mg three times day, Furthermore an intravenous vasopressor (IV norepinephrine). Results: The midodrine group had a higher APACHE II score compared to the control group (P=0.009).Midodrine significantly reduced the requirement for HD or MV, which in turn reduced the length of time patients spent in the intensive care unit (ICU) and the associated costs.Midodrine has a beneficial effect on ICU costs. The period of intravenous injection of nor-epinephrine is favourably affected by midodrine.  Conclusions: The study's authors state that midodrine has the potential to aid resuscitated patients with septic shock in weaning off intravenous vasopressors, which would have many economic benefits, such as reduced total expenditures and shorter stays in the critical care unit. Midodrine may be helpful in treating patients with septic shock.